Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06942182
Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
Double Blind Placebo-Controlled Parallel Group Study Of Safety And Efficacy Of Isomyosamine In Treating Sarcopenia After Hip Or Femoral Fracture In Gerontological Population
Sponsor: TNF Pharmaceuticals, Inc.
Interventions
Isomyosamine 250mg Placebo 250 mg
Updated 1 time since 2025 Last updated: Apr 16, 2025 Started: May 1, 2025 Primary completion: Mar 1, 2026 Completion: Mar 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06942182, this PHASE2 trial focuses on Frailty and Frailty in Older Adults and remains actively recruiting participants. Sponsored by TNF Pharmaceuticals, Inc., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- TNF Pharmaceuticals, Inc.
Data source: TNF Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.